PARIS—Drug companies are beginning early-stage research to develop a new vaccine against the rapidly spreading Zika virus, joining the race to control an outbreak that the World Health Organization said constitutes a global public-health emergency.
To attack Zika, French drugmaker Sanofi SA said Tuesday it would take advantage of the research it did for its newly approved vaccine for dengue fever—the world’s first against the mosquito-borne illness. The Zika and dengue viruses are in the same family.
U.S. biotech company NewLink Genetics Corp. said it too was working on developing treatment options for the disease.
Last month, GeneOne Life Science Inc., a South Korean biopharmaceutical company, said it had launched a joint research program with U.S. biotech firm Inovio Pharmaceuticals to develop a DNA-based vaccine to prevent and treat the Zika virus infection. U.K. drugmaker GlaxoSmithKline also said last week that it was assessing its research platform for the potential to develop a Zika vaccine.
FInancial Highlights (Gurufocus)
Sanofi ADR (SNY)
Operating margin (%) 18.87
Net-margin (%) 13.34
ROE (%) 14.77
Dividend Yield 3.90
Dividend Payout 79%
Dividend Growth (3y) 3.80%